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INTRODUCTION
Evidence gathered over the past two decades indicates that 
colon cancer sidedness is an emerging prognostic factor. Right-
sided colon cancer (RCC) shows distinct clinicopathological 
characteristics and long-term patient outcomes compared with 
left-sided colon cancer (LCC). Multiple studies have identified 
differential tumor biology as the reason for differences in 
patient prognoses for these 2 diseases [1-5]. RCC is more 
common in women and the elderly and these tumors are 
marked by a higher prevalence of poorly differentiated 
histology, microsatellite instability (MSI-H), and CpG island 
methylation than seen in LCC tumors. In addition, RCC is fre-
quently associated with driver gene mutations in KRAS and 
BRAF [6-8].
Generally, RCC is associated with worse survival outcomes 
than LCC. However, reports regarding the prognostic role of 
primary tumor location with respect to colon cancer stage are 
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Purpose: Previous studies have reported conflicting results regarding the prognostic value of tumor sidedness in colon 
cancer. We investigated the oncologic impact of tumor location and examined whether recurrence patterns were related to 
tumor sidedness in colon cancer patients. 
Methods: We identified stage I–III colon adenocarcinoma patients from a prospective colorectal cancer registry at 
Severance Hospital, Seoul, Korea, who underwent complete mesocolic excision between 2005 and 2012. Adjusted hazard 
ratios (HRs) and 95% confidence intervals (CI) for predictors of cancer-specific survival (CSS), recurrence-free survival 
(RFS), and cumulative recurrence at specific anatomic sites were examined using Cox proportional hazard regression 
analysis. 
Results: Overall, 1,912 patients, 1,077 (56.3%) with left-sided colon cancer (LCC), and 835 (43.7%) with right-sided colon 
cancer (RCC), at a median follow-up of 59 months, were eligible and included in the study. In univariate analysis, similar 
5-year CSS and RFS were observed for LCC and RCC in the total patient population, and when stratified by stage for stage 
I and II patients. For stage III patients, an adjusted Cox regression analysis indicated that RCC patients had a higher risk of 
cancer-specific mortality (HR, 1.75; 95% CI, 1.07–2.86; P = 0.024) and recurrence (HR, 1.78; 95% CI, 1.22–2.60; P = 0.003). 
Furthermore, RCC was an independent predictor of peritoneal recurrence (HR, 1.86; 95% CI, 1.05–3.29; P = 0.031) in stage 
III patients.
Conclusion: RCC correlated with worse CSS and RFS than LCC. In stage III patients, RCC correlated with increased risk of 
peritoneal recurrence. The reasons for these differences remain to be investigated.
[Ann Surg Treat Res 2019;96(6):296-304]
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conflicting [3,9]. For example, Warschkow et al. [3] showed 
that cancer-specific survival (CSS) was better in RCC patients 
than in LCC patients (adjusted hazard ratio [HR] for RCC, 0.90; 
95% confidence interval [CI], 0.87–0.93; P < 0.001). In stage 
III patients, RCC and LCC had similar prognoses, whereas 
prognosis was better for stage I and II RCC patients than LCC 
patients after propensity score matching [3]. Further, neither 
the Warschkow study nor most prior studies addressed the 
question of whether cancer recurrence patterns are related 
to tumor laterality [10]. Therefore, in-depth investigations of 
survival and recurrence patterns between RCC and LCC are 
warranted. In this study, we examined both the prognostic role 
of tumor sidedness in stage I–III colon cancer and patterns of 
recurrence with respect to tumor location.
METHODS
The study protocol was approved by the Institutional Review 
Board of the Human Research Protection Center, Severance 
Hospital, Seoul, South Korea (approval number: 4-2018-0682). 
Informed consent was waived due to the retrospective analysis 
of this study. 
Patients
Consecutive patients from a colorectal cancer registry who 
underwent surgical resection for colon cancer from November 
2005 to October 2012 at Severance Hospital, Yonsei University 
College of Medicine, Seoul, South Korea were selected for this 
study. Analysis of the data was performed in March 2018. 
Patient samples were staged according to the American Joint 
Commission on cancer stage I, II, III colon adenocarcinoma, 
based on pathology. Tumor locations were assigned through 
the patients’ medical records. Tumors proximal to the hepatic 
flexure were classified as RCC, and tumors located on the 
splenic flexure, descending and sigmoid colon were classified 
as LCC. The embryological reference point dividing RCC and 
LCC was the distal one third of the transverse colon. Because 
dividing the transverse colon into thirds can be ambiguous, 
transverse colon cancer was excluded from the study. Patients 
with tumors originating from the appendix (n = 35) and 
rectosigmoid junction (n = 247) or who received palliative 
resection (n = 174), resection for synchronous colon cancer 
(n = 80), or who had distant metastases (n = 441) were also 
excluded. 
Surgical technique
As previously described, all patients underwent surgical 
resections based on the principle of complete mesocolic excision 
with central vascular ligation (CME with CVL) [11]. Briefly, en 
bloc resection included the tumor and its surrounding soft 
tissue enveloped by intact visceral fascia. Supplying vessels 
were ligated at their origin to achieve CVL. Specimens included 
pericolic, intermediate, and principal lymph nodes for adequate 
lymphadenectomy. If the tumor was suspected to have invaded 
or threatened the CME plane on the retroperitoneal side in the 
ascending or descending colon, we deepened our dissection to 
include perinephric fat tissues in the en bloc specimen.
Outcome measurements 
Primary outcomes measured in this study were CSS, recur-
rence-free survival (RFS), and cumulative recurrence rate by 
specific anatomic site. CSS was defined as the length of time 
from the date of curative resection to the date of death from 
colon cancer. Patients who died of other causes were censored. 
RFS was defined as the length of time the patient survived 
without any evidence of colon cancer following primary tumor 
resection. Cumulative incidence of recurrence was defined as 
the probability that colon cancer recurrence had occurred before 
the given time. Patients who died without recurrence were 
censored. 
Statistical analysis
 Comparison of all variables between RCC and LCC was 
conducted using a chi-square test for categorical variables, 
and either Mann-Whitney’s U test or independent t-test for 
continuous variables. The frequency of recurrence by site and 
stage was determined using rates and relative risk with a 95% 
confidence interval (CI). For long-term outcomes, Kaplan-Meier 
curves were drawn and log-rank tests were used to compare 
RCC and LCC. Multivariate Cox regression was performed to 
assess the effect of tumor location after adjusting for covariates. 
All tests were 2-sided, and P-values <0.05 were considered 
statistically significant. Statistical analysis was performed using 
SPSS software, version 20.0 (IBM Corp.).
RESULTS
Clinicopathological characteristics 
Of the 1912 patients included in the study, 835 (43.7%) 
underwent right colectomy and 56.3% (n = 1,077) underwent 
left colectomies or sigmoid colectomy. RCC was more common 
in older patients and female patients. Other clinical features 
such as body mass index (BMI) and American Society of 
Anesthesiologists (ASA) physical status classification (III, IV) 
did not show significant differences between RCC and LCC. 
Prognostic nutritional index (PNI), an immunological and 
nutritional marker related to short- and long-term outcomes, 
was better in LCC patients [12,13].
Histological grade was higher, tumor size was larger, and 
invasion was deeper in RCC, whereas metastatic nodal status 
and the rate of lymphovascular invasion (LVI) were similar. RCC 
specimens contained more regional lymph nodes than did LCC 
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specimens (Table 1).
Surgical characteristics and perioperative outcomes
Minimally invasive surgery was used more frequently in LCC 
than RCC. Minimally invasive surgeries were more commonly 
converted to open surgeries with RCC, and RCC surgeries had 
longer operation times and more significant blood loss than 
LCC surgeries. Although the proportion of patients undergoing 
multivisceral resection was similar between groups, nine cases 
(1.1%) of RCC, but none of LCC, required duodenum resection to 
achieve complete R0 resection. The proportion of patients who 
underwent adjuvant chemotherapy was comparable between 
Table 1. Clinicopathological characteristics of all included patients
Characteristic LCC (n = 1,077) RCC (n = 835) P-value
Age (yr) 62 (53–70) 63 (56–71) <0.001
Male sex 654 (60.7) 461 (55.2) 0.015
Body mass index (kg/m2) 23.3 (21.3–25.4) 23.2 (21.4–25.3) 0.339
ASA PS classification ≥ III 189 (17.5) 151 (18.1) 0.762
PNIa) < 50 317 (29.4) 359 (43.0) <0.001
Obstruction 36 (3.3) 24 (2.9) 0.560
Tumor size > 5 cm 267 (24.8) 327 (39.2) <0.001
AJCC stage <0.001
    I 279 (25.9) 174 (20.8)
    II 378 (35.1) 365 (43.8)
    III 420 (39.0) 295 (35.3)
T stage 0.001
    1 177 (16.4) 105 (12.6)
    2 153 (14.2) 97 (11.6)
    3 645 (59.9) 515 (61.7)
    4 102 (9.5) 118 (14.1)
N stage 0.231
    0 657 (61.0) 541 (64.8)
    1 291 (27.0) 206 (24.7)
    2 129 (12.0) 88 (10.5)
No. of examined LNs 16 (11–23) 27 (19–37) <0.001
Harvested LN < 12 285 (26.5) 48 (5.7) <0.001
LVI 247 (23.9) 196 (24.2) 0.884
Histologic grade <0.001
    G1, 2 1,026 (95.3) 727 (87.1)
    G3, 4 51 (4.7) 108 (12.9)
Values are presented as median (interquartile range) or number (%).
LCC, left-sided colon cancer; RCC, right-sided colon cancer; ASA PS, American Society of Anesthesiologists physical status; PNI, 
prognostic nutritional index; AJCC, American Joint Committee on Cancer; LN, lymph node; LVI, lymphovascular invasion.
a)PNI = 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (cells/mm3).
Table 2. Surgical characteristics and perioperative outcomes
Variable LCC (n = 1,077) RCC (n = 835) P-value
MIS 815 (75.7) 555 (66.5) <0.001
Surgical duration (min) 192 (153–242) 207 (171–254) <0.001
EBL ≥ 200 mL 181 (16.8) 201 (24.1) <0.001
Open conversion 13/815 (1.6) 25/555 (4.5) 0.001
Multivisceral resection 36 (3.3) 32 (3.8) 0.566
30-Day mortality 1 (0.1) 1 (0.1) >0.999
30-Day morbidity 91 (9.3) 124 (16.2) <0.001
Hospital stay (day) 8 (6–11) 9 (7–12) <0.001
Adjuvant chemotherapy 630 (58.5) 491 (58.9) 0.868
Values are presented as number (%) or median (interquartile range).
LCC, left-sided colon cancer; RCC, right-sided colon cancer; MIS, minimally invasive surgery; EBL, estimated blood loss.
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the 2 groups (Table 2). 
Survival and recurrence
Differences in 5-year CSS between RCC and LCC for all 
stages combined (91.9% vs. 94.7%, P = 0.110), and for stage I 
(100% vs. 99.6%, P = 0.273), and stage II (95.8% vs. 97.1%, 
P = 0.739) cancers were not observed in unadjusted survival 
analyses. Further, unadjusted survival curves demonstrated 
no significant differences in the 5-year RFS between RCC 
and LCC for all stages combined (85.6% vs. 88.0%, P = 0.079), 
and for stage I (98.3% vs. 97.0%, P = 0.325), and stage II (88.9% 
vs. 90.2%, P = 0.681) cancers. However, for stage III patients, 
unadjusted Cox regression showed an increased risk for both 
cancer-specific mortality (HR, 1.53; 95% CI, 1.02–2.30; P = 
0.037) and recurrence (HR, 1.56; 95% CI, 1.13–2.14; P =0.006) for 
RCC compared with LCC (Fig. 1A, B). Subsequent multivariable 
analysis for CSS and RFS were performed with possible 
confounders including age, sex, BMI, ASA physical status 
classification, PNI, obstruction, tumor size, histologic grade, LVI, 
adjuvant chemotherapy, number of examined lymph nodes, 
estimated blood loss (EBL), T stage, and number of positive LN 
in stage III. After adjustment, RCC patients had a higher risk of 
cancer-specific mortality (HR, 1.75; 95% CI, 1.07–2.86; P = 0.024) 
and recurrence (HR, 1.78; 95% CI, 1.22–2.60; P = 0.003) (Table 3). 
When all recurrences were stratified by stage and site, the 
recurrence rate for all sites was higher only in stage III RCC 
(27.0% vs. 18.6%, P = 0.012), and peritoneal recurrence (PR) 
was approximately twice as frequent in RCC (12.5%) than LCC 
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Fig. 1. Kaplan-Meier curves for survival analysis within stage III colon cancer patients. Cancer specific survival (CSS) (A), 
recurrence-free survival (RFS) (B), peritoneal recurrence (PR) (C), CSS from recurrence to death (CSS2) according to presence of 
peritoneal recurrence (D), and CSS2 in patients with peritoneal recurrence (E). LCC, left-sided colon cancer; RCC, right-sided 
colon cancer.
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(6%) (Table 4). Five-year cumulative incidence of PR showed 
significant difference between RCC and LCC in stage III colon 
cancer (13.7% vs. 6.5%; P = 0.002) (Fig. 1C). A subsequent Cox 
proportional hazard regression for PR was conducted including 
all clinical and pathological variables. The locational impact of 
the tumor on PR in stage III patients persisted following ad-
justed analysis (Table 5).
CSS after recurrence (CSS2), was defined as the period be-
tween the date that recurrence was initially recognized and 
the date of either death from colon cancer or the last follow-
up. The Kaplan-Meier curve and log rank test for stage III colon 
cancer revealed that patients with PR had significantly worse 
CSS2 than those without PR (Fig. 1D). Further comparison of 
CSS2 between RCC and LCC showed no differences in stage 
III patients with PR (Fig. 1E). In multivariable Cox regression 
analysis of stage III patients, peritoneal metastases exhibited 
worse results for CSS2 (HR, 1.55; 95% CI, 1.03–2.34; P = 0.035), 
after adjusting metastases from other sites (Table 6).
Table 3. Multivariate analysis for cancer specific- and recurrence free survival in patients stratified by stage
All stages (n = 1,912) Stage I (n = 453) Stage II (n = 743) Stage III (n = 715)
HRa) (95% CI) P-value HRa) (95% CI) P-value HRa) (95% CI) P-value HRa) (95% CI) P-value 
CSS 1.06 (0.69–1.62) 0.781 0.50 (0.0–99.9)b) 0.998 0.61 (0.27–1.39) 0.248 1.75 (1.07–2.86) 0.024
RFS 1.12 (0.81–1.54) 0.476 1.50 (0.16–13.4) 0.713 0.78 (0.45–1.35) 0.388 1.78 (1.22–2.60) 0.003
Covariates: age, sex, BMI, ASA PS classification, PNI, obstruction, tumor size, AJCC stages, histologic grade, LVI, adjuvant 
chemotherapy, No. of examined lymph nodes, EBL.
HR, hazard ratio; CI, confidence interval; CSS, cancer specific survival; RFS, recurrence free survival; BMI, body mass index; ASA PS, 
American Society of Anethesiologists physical status; PNI, prognostic nutritional index; AJCC, American Joint Committee on Cancer; 
LVI, lymphovacular invasion; EBL, estimated blood loss.
a)Comparing right colon cancer with left colon cancer. b)95% confidence interval of stage I was very wide due to only one event was 
noted during follow-up. 
Table 4. Details of recurrence during follow-up
Variable LCC RCC Relative risk (95% CI) P-value
Follow-up duration (mo) 68.1 (53.9–86.9) 67.7 (52.0–85.5) - 0.724
Recurrences in all patients 119 (11.0) 115 (13.8) 1.28 (0.97–1.69) 0.072
Recurrences by stage and site
    Stage I 2 (1.3) 6 (2.5) 1.92 (0.38–9.67) 0.417
        Liver 1 (0.6) 2 (0.7) 1.27 (0.11–14.14) 0.844
        Lung 0 (0) 2 (0.7) - 0.259
        Bone 0 (0) 2 (0.7) - 0.526
        Peritoneal 0 (0) 1 (0.4) - 0.999
        Extraregional LN 0 (0) 1 (0.4) - 0.999
        Locoregional 1 (0.6) 0 (0) - 0.384
    Stage II 38 (10.1) 36 (9.8) 0.97 (0.60–1.57) 0.921
        Liver 16 (4.2) 11 (3.0) 0.70 (0.32–1.53) 0.371
        Lung 10 (2.6) 12 (3.3) 1.24 (0.53–2.92) 0.610
        Bone 0 (0) 1 (0.3) - 0.492
        Peritoneal 12 (3.2) 13 (3.6) 1.12 (0.50–2.49) 0.775
        Extraregional LN 2 (0.8) 4 (1.1) 1.38 (0.30–6.21) 0.721
        Locoregional 6 (1.6) 4 (1.1) 0.68 (0.19–2.44) 0.753
    Stage III 78 (18.6) 79 (27.0) 1.65 (1.15–2.37) 0.012
        Liver 24 (5.7) 20 (6.8) 1.20 (0.65–2.21) 0.559
        Lung 22 (5.2) 18 (6.1) 1.17 (0.61–2.23) 0.621
        Bone 1 (0.2) 2 (0.7) 2.86 (0.25–31.68) 0.370
        Peritoneal 25 (6.0) 37 (12.5) 2.26 (1.33–3.85) 0.002
        Extra-regional LN 12 (2.9) 13 (4.4) 1.56 (0.70–3.48) 0.267
        Locoregional 7 (1.7) 10 (3.4) 2.07 (0.77–5.50) 0.137
Values are presented as median (interquartile range) or number (%).
LCC, left-sided colon cancer; RCC, right-sided colon cancer; CI, confidence interval; LN, lymph node.
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Table 5. Multivariable analysisa) for peritoneal recurrence in stage III colon cancer patients
Variable
Unadjusted analysis Adjusted analysis
HR (95% CI) P-value HR (95% CI) P-value
Right colon cancer 2.24 (1.33–3.75) 0.002 1.86 (1.05–3.29) 0.031
Age 0.98 (0.96–1.01) 0.988 - -
Male sex 0.55 (0.33–0.93) 0.026 0.62 (0.36–1.07) 0.091
ASA PS classification ≥ 3 0.96 (0.47–1.95) 0.914 - -
Body mass index 0.88 (0.81–0.96) 0.006 0.94 (0.86–1.03) 0.195
PNI < 50 0.55 (0.33–0.92) 0.024 0.94 (0.52–1.69) 0.848
Obstruction 2.70 (1.22–5.94) 0.013 2.52 (1.08–5.90) 0.032
Tumor size > 5 cm 1.73 (1.04–2.87) 0.034 0.95 (0.54–1.68) 0.876
Histologic grade 3, 4 3.23 (1.84–5.67) <0.001 2.04 (1.10–3.80) 0.023
LVI 1.84 (1.09–3.08) 0.021 1.36 (0.78–2.38) 0.271
T 3, 4 7.65 (1.06–55.25) 0.044 4.37 (0.59–32.23) 0.148
No. of positive LNs 1.13 (1.07–1.20) <0.001 1.08 (1.02–1.15) 0.007
Adjuvant chemotherapy 0.44 (0.20–0.98) 0.045 0.42 (0.18–0.95) 0.039
Examined LN < 12 1.15 (0.55–2.43) 0.701 - -
EBL ≥ 200 mL 2.12 (1.24–3.63) 0.006 1.62 (0.91–2.89) 0.097
HR, hazard ratio; CI, confidence interval; ASA PS, American Society of Anethesiologists physical status; PNI, prognostic nutritional 
index; LVI, lymphovascular invasion; LN, lymph node; EBL, estimated blood loss.
a)After all variables that showed P ≥ 0.2 in univariate analysis were removed, multivariable Cox regression analysis was performed 
using the enter method.
Table 6. Multivariable analysisa) for cancer specific survival after recurrence in stage III patients
Unadjusted analysis Adjusted analysis
HR (95% CI) P-value HR (95% CI) P-value
Right colon cancer 1.45 (0.98–2.15) 0.061 1.21 (0.79–1.83) 0.371
Age 1.00 (0.98–1.01) 0.900 - -
Male sex 1.04 (0.69–1.56) 0.852 - -
ASA PS classification ≥ 3 1.24 (0.75–2.07) 0.388 - -
Body mass index 1.01 (0.95–1.08) 0.611 - -
PNI < 50 1.12 (0.74–1.68) 0.586 - -
Obstruction 1.37 (0.21–4.26) 0.524 - -
Tumor size > 5 cm 0.98 (0.65–1.49) 0.949 - -
Histologic grade 3, 4 1.86 (1.17–2.96) 0.009 1.34 (0.82–2.20) 0.238
LVI 1.26 (0.83–1.91) 0.263
T3, 4 0.96 (0.30–3.05) 0.954
No. of positive LN 1.06 (0.97–1.16) 0.065 1.03 (0.89–1.24) 0.174
Adjuvant chemotherapy 1.30 (0.65–2.60) 0.443 - -
Examined LN < 12 0.76 (0.42–1.36) 0.361 - -
EBL ≥ 200 mL 1.19 (0.77–1.85) 0.423 - -
Liver metastases 0.88 (0.55–1.39) 0.598 - -
Lung metastases 0.90 (0.56–1.44) 0.673 - -
Bone metastases 1.51 (0.37–6.19) 0.564 - -
Extra regional LN metastases 1.74 (1.04–2.89) 0.033 1.44 (0.86–2.43) 0.163
Locoregional metastases 0.96 (0.51–1.82) 0.922 - -
Peritoneal metastases 1.70 (1.13–2.56) 0.011 1.55 (1.03–2.34) 0.035
HR, hazard ratio; CI, confidence interval; ASA PS, American Society of Anethesiologists physical status; PNI, prognostic nutritional 
index; LVI, lymphovascular invasion; LN, lymph node; EBL, estimated blood loss.
a)After all variables that showed P ≥ 0.2 in univariate analysis were removed, multivariable Cox regression analysis was performed 
using the enter method.
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DISCUSSION
Consistent with prior studies, we found that stage III RCC 
patients had worse prognoses than stage III LCC patients. 
However, we did not detect significant differences in CSS or RFS 
between RCC and LCC in either our total patient population 
or in patients with stage I or stage II disease. Other studies 
have reported conflicting findings at different cancer stages, 
although the majority showed worse prognosis for stage III RCC 
patients [1,2]. The most likely explanation for not uncovering 
differences in the survival of stage I and II patients in this 
study is a lack of statistical power due to our relatively small 
sample size. Other studies, for example those that rely on the 
SEER (Surveillance, Epidemiology, and End Results Program), 
have data for tens of thousands of patients. Another possible 
reason for recovering differences only in stage III patients is 
that the radical lymphadenectomies performed in this study 
effectively removed remnant tumor cells from stage I and 
II patients, but not from stage III RCC patients, resulting in 
worse oncologic outcomes for this group. In this context, the 
extensive lymphadenectomies performed in this study may 
have minimized the influence of tumor sidedness on stage 
I and II patient outcomes, precluding sidedness as a useful 
prognostic factor for these patients. The median number of 
regional lymph nodes removed during surgery in this study 
was 27 for RCC and 16 for LCC, comparable with prospective 
studies in which surgeons performed CME [14]. In line with 
more complete resections impacting outcome, Ishihara et al. [15] 
showed that tumor location was not a significant predictor of 
CSS in patients with R0 resection (both primary and metastatic 
tumors), whereas RCC was associated with worse prognosis 
in patients with palliative resection. They speculated that 
“radicality of surgery may mitigate the difference in biological 
aggressiveness between RCC and LCC” [15]. This indicates that 
surgical completeness or quality may be particularly important 
for advanced RCC. 
Another key finding of this study is that RCC significantly 
raises the risk of PR in stage III patients (HR, 1.86; 95% CI, 
1.05–3.29; P = 0.031). Peritoneal metastasis is generally 
thought to result from direct implantation of cancer cells via 
serosal invasion, extravasation of cancer cells from perforated 
or obstructed bowel, and leakage of tumor cells from severed 
lymphatics or veins [16]. Our data showed the risk of PR was 
higher in stage III RCC after adjusting for known risk factors 
such as age, T stage, number of metastatic nodes, obstruction, 
and adjuvant chemotherapy [17].
The cause for frequent occurrence of peritoneal metastasis in 
RCC is not clear, but it is thought to be related to tumor biology. 
Mutations in BRAF and microsatellite instability (MSI) are more 
common in RCC than LCC [18,19]. Tran et al. [20] compared 
colon tumors with and without BRAF mutations and found 
higher rates of peritoneal metastases (46% vs. 24%, P = 0.001), 
and poorer overall survival (10.4 months vs. 34.7 months, P < 
0.001) in patients with mutant tumors. Further, tumors with 
BRAF mutations frequently display adverse histological features 
such as lymphatic invasion, perineural invasion, high tumor 
budding, and mucinous and signet-ring cell histology [19].
Mismatch repair (MMR) genes are also frequently mutated 
in colon cancer. MMR deficiency can be assessed by examining 
MSI as a proxy for compromised MMR. However, few studies 
have examined cancer recurrence patterns with respect to 
MMR deficiency. Kim et al. [21] reported peritoneal metastases 
were more common in MSI-high tumors, compared with MSI-
low/microsatellite stable tumors, in stages I–III colorectal cancer 
(40.0% vs. 12.3%, P = 0.003). They also demonstrated that MSI-
high status was a predictor of worse overall survival in patients 
with recurrence (HR, 1.36; P = 0.035). Because BRAF mutation 
status was not available for this study, we examined MMR 
status with respect to tumor location. We noted that MSI-high 
status was significantly more common in RCC than LCC (12.4% 
vs. 6.3%; P = 0.021) (Supplementary Table 1), supporting the 
idea that tumor biology might underlie the frequent PRs seen in 
stage III RCC patients. 
Peritoneal metastasis is a powerful negative prognostic 
factor in colorectal cancer. The prognosis for patients with isol-
ated peritoneal metastases is equally as poor for patients with 
multiple-organ metastases [22,23]. In this study, patients with 
PR had a worse prognosis with respect to CSS2 than those with 
other types of recurrences, and PR was a predictor of CSS2 
after adjusting for other site recurrences in stage III patients. 
Survival after PR was similar for both RCC and LCC patients. 
We also found no difference in the rate of curative resection 
as a treatment for recurrence in LCC and RCC patients (50.0% 
for LCC and 40.3% for RCC; P = 0.383) (Supplementary Table 
2). The presence of PR seems to be a major contributor to the 
differences in survival of patients with stage III RCC and LCC. 
Mutations in KRAS that confer tumors resistant to anti-
epidermal growth factor receptor (EGFR) antibody-based 
therapies are likely to contribute to the lower survival rates of 
RCC patients. Patients with KRAS mutations are precluded from 
anti-EGFR antibody-based treatments for metastatic colorectal 
cancer (mCRC). However, even in the absence of KRAS 
mutations, RCC patients may have worse outcomes. A recent 
meta-analysis of 6 randomized trials compared chemotherapy 
coupled with anti-EGFR antibody treatment (experimental arm) 
to chemotherapy alone and to chemotherapy coupled with 
bevacizumab (an anti-vascular endothelial growth factor (VEGF) 
antibody) treatment (control arms) in mCRC patients with wild-
type RAS. Overall survival and progression-free survival were 
improved in LCC patients, but not RCC patients, treated with 
anti-EGFR antibody [24]. This suggests that tumor location may 
be a predictor of anti-EGFR antibody therapy efficacy. 
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This study has several limitations. First, despite efforts to 
collect complete and accurate data, a retrospective review of 
patients from a single institution may diminish the reliability 
and generality of the results. For instance, primary tumor 
location may be reported differently by different surgeons, 
especially in cases of rectosigmoid junction tumors. However, 
a strength of this study is that treatment variability was likely 
minimized as treatments were performed at a single institution 
over a relatively short time period (7 years). Second, molecular 
profiling data for tumors was limited. BRAF and KRAS status 
was not available, which prevented testing the hypothesis that 
BRAF and KRAS mutations result in a worse prognosis for stage 
III RCC patients. 
Despite our current understanding of how molecular profiles 
vary according to tumor location, the chief molecules and 
pathways that lead to better and worse outcomes for LCC and 
RCC, respectively, are still unknown. Thus, studies of LCC and 
RCC patient populations bearing defined tumor genotypes will 
be required to reveal the how tumor location predicts patient 
survival.
In conclusion, right-sided colon tumors have worse CSS and 
RFS, mainly due to the higher risk of PR in stage III colon cancer 
patients. This suggests that primary tumor location might serve 
as a biomarker for predicting peritoneal recurrence. The reason 
for this observation may be due to differences in LCC and RCC 
tumor biology that remain to be uncovered. 
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